Benjamin Hohl - CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Chief Financial Officer
Issuer Symbol
ELVN on Nasdaq
All Insider Reports
All Insider Reports

Benjamin Hohl - trading volume in the past year for Enliven Therapeutics, Inc.

Holdings reported by Benjamin Hohl for Enliven Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 61,000 $1,548,180 $25.38 12 Feb 2026 Direct
Stock Option (right to buy) 150,000 12 Feb 2026 Direct Common Stock

Transactions reported by Benjamin Hohl for Enliven Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.